Abstract
The eukaryotic translation initiation factor eIF4E is elevated in many human cancers. Tissue-specific targeting of eIF4E activity in ovarian cancer cells is achieved in cell culture and in mice by fusing a peptide corresponding to the eIF4E inhibitor, the eIF4E binding protein 1 (BP1), to an agonist of the gonadotropin receptor.
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Drug Delivery Systems / methods*
-
Eukaryotic Initiation Factor-4E / antagonists & inhibitors*
-
Eukaryotic Initiation Factor-4E / physiology
-
Female
-
Gonadotropin-Releasing Hormone / agonists
-
Humans
-
Mice
-
Mice, Knockout
-
Models, Biological
-
Ovarian Neoplasms / drug therapy*
-
Recombinant Fusion Proteins / administration & dosage
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
Eukaryotic Initiation Factor-4E
-
Recombinant Fusion Proteins
-
Gonadotropin-Releasing Hormone